CCR7+ activated dendritic cells are essential for spontaneous and immunotherapy-driven anti-tumor immunity
(1) Koufaki MA (2) Richardson E (3) Bonavita E (4) Reeves R (5) Moeini A (6) Chiang SC (7) Banyard A (8) Russo M (9) Earnshaw CH (10) Bell CR (11) Flanagan E (12) Pelly VS (13) Nebot-Bral L (14) Pidoux A (15) Dunn P (16) Sahoo S (17) Henri S (18) Malissen B (19) MacDonald AS (20) Moncaut N (21) Zelenay S
Koufaki et al. developed murine models to label and ablate activated CCR7+ DCs (actDCs) to study their role in tumor immunity. The activated state was shared by cDC1s and cDC2s, and was essential for priming in TDLNs, using cross-presentation for actcDC1s and cross-dressing for actcDC2s. Further, absence of actDCs resulted in reduced tumor-specific CD8+ T cells and reduced antitumor responses. ActDCs were also essential for the efficacy of ICB and ACT treatment in murine tumor models.
(1) Koufaki MA (2) Richardson E (3) Bonavita E (4) Reeves R (5) Moeini A (6) Chiang SC (7) Banyard A (8) Russo M (9) Earnshaw CH (10) Bell CR (11) Flanagan E (12) Pelly VS (13) Nebot-Bral L (14) Pidoux A (15) Dunn P (16) Sahoo S (17) Henri S (18) Malissen B (19) MacDonald AS (20) Moncaut N (21) Zelenay S
Koufaki et al. developed murine models to label and ablate activated CCR7+ DCs (actDCs) to study their role in tumor immunity. The activated state was shared by cDC1s and cDC2s, and was essential for priming in TDLNs, using cross-presentation for actcDC1s and cross-dressing for actcDC2s. Further, absence of actDCs resulted in reduced tumor-specific CD8+ T cells and reduced antitumor responses. ActDCs were also essential for the efficacy of ICB and ACT treatment in murine tumor models.
ABSTRACT: Single-cell transcriptomics identifies a convergent activation state of conventional dendritic cells (cDCs) shared by type 1 and type 2 cDCs (cDC1s and cDC2s). These activated DCs (actDCs) are characterized by co-expression of T cell-stimulating and inhibitory molecules. Here, we examined the functional contribution of actDCs to anti-tumor immunity by developing mouse models that leverage CCR7 expression to conditionally label or ablate actDCs. The capacity of cDCs to stimulate tumor-specific cytotoxic T lymphocytes (CTLs) was restricted to the actDC state. cDC1- and cDC2-derived actDCs supported CTL priming through cross-presentation and cross-dressing, respectively, with the latter occurring in a cancer type-dependent manner. actDCs were required for the activation of naive CTLs in tumor-draining lymph nodes and for sustaining effector CTL function within tumors. Consequently, ablation of actDCs impaired spontaneous tumor control and responses to immune checkpoint blockade or adoptive T cell therapy. Thus, the actDC state emerges as a critical determinant of cDC-mediated anti-tumor immunity.
Author Info:
(1) Cancer Inflammation and Immunity, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. (2) Cancer Inflammation and Immunity, Cancer Research U
K Manchester Institute, The University of Manchester, Manchester, UK. (3) Cancer Inflammation and Immunity, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. (4) Computational Biology Support, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. (5) Cancer Inflammation and Immunity, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. (6) Cancer Inflammation and Immunity, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. (7) Flow Cytometry, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. (8) Cancer Inflammation and Immunity, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. (9) Cancer Inflammation and Immunity, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK; Dermatology Centre, Northern Care Alliance NHS Foundation Trust & Division of Musculoskeletal and Dermatological Sciences, Manchester NIHR Biomedical Research Centre, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK. (10) Cancer Inflammation and Immunity, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. (11) Cancer Inflammation and Immunity, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. (12) Cancer Inflammation and Immunity, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. (13) Cancer Inflammation and Immunity, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. (14) Cancer Inflammation and Immunity, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. (15) Cancer Inflammation and Immunity, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. (16) Computational Biology Support, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. (17) Centre d'Etude des Pathologies Respiratoires, INSERM, UMR 1100, Universit de Tours, Tours, France. (18) Centre d'Immunologie de Marseille-Luminy, INSERM, CNRS, Aix Marseille Universit, Marseille, France; Centre d'Immunophnomique, INSERM, CNRS, PHENOMIN, Celphedia, Aix Marseille Universit, Marseille, France. (19) Lydia Becker Institute of Immunology and Inflammation, The University of Manchester, Manchester, UK. (20) Genome Editing and Mouse Models, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK. (21) Cancer Inflammation and Immunity, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK; Lydia Becker Institute of Immunology and Inflammation, The University of Manchester, Manchester, UK. Electronic address: santiago.zelenay@cruk.manchester.ac.uk.